69,708 Shares in Moderna, Inc. (NASDAQ:MRNA) Purchased by Banque Transatlantique SA

Banque Transatlantique SA acquired a new stake in Moderna, Inc. (NASDAQ:MRNA) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 69,708 shares of the company’s stock, valued at approximately $2,858,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB boosted its position in shares of Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after buying an additional 587 shares during the period. Venturi Wealth Management LLC raised its stake in Moderna by 286.2% during the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after acquiring an additional 664 shares in the last quarter. Compass Planning Associates Inc bought a new position in shares of Moderna in the fourth quarter worth $37,000. Crowley Wealth Management Inc. acquired a new position in shares of Moderna during the fourth quarter valued at $41,000. Finally, Itau Unibanco Holding S.A. increased its holdings in shares of Moderna by 51.2% during the fourth quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company’s stock valued at $42,000 after purchasing an additional 343 shares during the period. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Stock Up 2.1 %

MRNA opened at $27.61 on Friday. Moderna, Inc. has a 12-month low of $23.15 and a 12-month high of $170.47. The firm has a market capitalization of $10.67 billion, a P/E ratio of -2.98 and a beta of 1.99. The stock has a fifty day moving average of $29.52 and a 200-day moving average of $37.46.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, topping analysts’ consensus estimates of ($2.92) by $0.40. The firm had revenue of $108.00 million during the quarter, compared to analyst estimates of $130.35 million. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. The business’s quarterly revenue was down 35.3% compared to the same quarter last year. During the same period last year, the company posted ($3.07) EPS. On average, analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. William Blair reiterated a “market perform” rating on shares of Moderna in a research report on Thursday, April 17th. Leerink Partners lowered their price objective on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a research note on Thursday, January 16th. Berenberg Bank upped their target price on Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a research report on Thursday, January 16th. Citigroup began coverage on Moderna in a research report on Thursday, March 13th. They set a “neutral” rating and a $40.00 price target on the stock. Finally, Barclays cut their price objective on Moderna from $45.00 to $40.00 and set an “equal weight” rating for the company in a report on Friday. Four research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $53.95.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.